Literature DB >> 7983571

Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates.

M E Lynch1, J D Sobel.   

Abstract

Although numerous antimycotic agents are available for the treatment of yeast vaginitis there is little comparative data on the in vitro activity of these drugs. In the present two-part study, in vitro macro-broth dilution sensitivity tests were performed on a total of 377 clinical vaginal yeast isolates of nine different species. Antimycotics surveyed included amphotericin B, 5-fluorocytosine and eight azole derivatives. Results show that all vaginal Candida albicans isolates were uniformly sensitive at low concentration to all 10 antimycotics tested. However, non-albicans species, especially Candida glabrata and Saccharomyces cerevisiae, manifested several-fold increases in minimal inhibitory concentrations to all azoles tested except butoconazole. In particular, the in vitro potency of fluconazole and terconazole against species other than C. albicans was relatively poor, whereas the drugs demonstrating the best activity were itraconazole, butoconazole and saperconazole. Susceptibility testing of vaginal C. albicans isolates is not routinely indicated, even in patients with recurrent vaginitis and should be reserved for selected organisms, especially non-albicans species, in patients with clinical failure only.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7983571

Source DB:  PubMed          Journal:  J Med Vet Mycol        ISSN: 0268-1218


  20 in total

Review 1.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

2.  Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections.

Authors:  D J White; A R Habib; A Vanthuyne; S Langford; M Symonds
Journal:  Sex Transm Infect       Date:  2001-06       Impact factor: 3.519

3.  Antimicrobial Resistance in Vulvovaginitis.

Authors:  Jack D. Sobel
Journal:  Curr Infect Dis Rep       Date:  2001-12       Impact factor: 3.725

4.  Pathogenesis of Recurrent Vulvovaginal Candidiasis.

Authors:  Jack D. Sobel
Journal:  Curr Infect Dis Rep       Date:  2002-12       Impact factor: 3.725

Review 5.  Fluconazole. An update of its antimicrobial activity, pharmacokinetic properties, and therapeutic use in vaginal candidiasis.

Authors:  C M Perry; R Whittington; D McTavish
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

6.  Phenotypic Characterization and Antifungal Susceptibility Pattern to Fluconazole in Candida species Isolated from Vulvovaginal Candidiasis in a Tertiary Care Hospital.

Authors:  Latha Ragunathan; G K Poongothai; Annie Rofeena Sinazer; Kavitha Kannaiyan; Hemalatha Gurumurthy; Nirmala Jaget; Sethumadhavan Kuthalaramalingam
Journal:  J Clin Diagn Res       Date:  2014-05-15

7.  Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria.

Authors:  C A Enwuru; A Ogunledun; N Idika; N V Enwuru; F Ogbonna; M Aniedobe; A Adeiga
Journal:  Afr Health Sci       Date:  2008-09       Impact factor: 0.927

Review 8.  Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.

Authors:  P L Fidel; J A Vazquez; J D Sobel
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

Review 9.  Management of patients with recurrent vulvovaginal candidiasis.

Authors:  Jack D Sobel
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications.

Authors:  J D Sobel; M Zervos; B D Reed; T Hooton; D Soper; P Nyirjesy; M W Heine; J Willems; H Panzer
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.